All In Biotech

Drug Trial Radar · NCT07237308

BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis

A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Jul 14, 2026

Primary completion

Jul 1, 2029

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Yonsei UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.

Conditions

  • Stroke
  • Ischemic
  • Atrial Fibrillation
  • Arteriosclerosis
  • Intracranial Arteriosclerosis

Interventions

  • ApixabanDrug

    Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.

  • ClopidogrelDrug

    Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committeeTime frame: At 30 ± 5 days after randomization

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Dong-A University Hospital

    Busan, South Korea · Recruiting

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Hallym University Chuncheon Sacred Heart Hospital

    Chuncheon, South Korea · Recruiting

  • Keimyung University Dongsan Hospital

    Daegu, South Korea · Recruiting

  • National Health Insurance Service Ilsan Hospital

    Goyang, South Korea · Recruiting

  • Catholic Kwandong University International St. Mary's Hospital

    Incheon, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • Inha University Hospital

    Incheon, South Korea · Recruiting

  • Ewha Womans University Seoul Hospital

    Seoul, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Hanyang University Seoul Hospital

    Seoul, South Korea · Recruiting

  • Inje University Sanggye Paik Hospital

    Seoul, South Korea · Recruiting

  • Kangbuk Samsung Hospital

    Seoul, South Korea · Recruiting

  • Kangdong Sacred Heart Hospital

    Seoul, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea · Recruiting

  • Kyung Hee University Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Yonsei University College of Medicine

    Seoul, South Korea · Recruiting

  • Yongin Severance Hospital

    Yŏngin, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.